1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Medulloblastomas with ELP1 pathogenic variants: A weakly penetrant syndrome with a restricted spectrum in a limited age window

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      Neuro-Oncology Advances
      Oxford University Press
      cancer predisposition syndrome, ELP1, medulloblastoma, pathogenic variant

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          ELP1 pathogenic variants (PV) have been recently identified as the most frequent variants predisposing to Sonic Hedgehog (SHH) medulloblastomas (MB); however, guidelines are still lacking for genetic counseling in this new syndrome.

          Methods

          We retrospectively reviewed clinical and genetic data of a French series of 29 ELP1-mutated MB.

          Results

          All patients developed SHH-MB, with a biallelic inactivation of PTCH1 found in 24 tumors. Other recurrent alterations encompassed the TP53 pathway and activation of MYCN/MYCL signaling. The median age at diagnosis was 7.3 years (range: 3–14). ELP1-mutated MB behave as sporadic cases, with similar distribution within clinical and molecular risk groups and similar outcomes (5 y – OS = 86%); no unusual side effect of treatments was noticed. Remarkably, a germline ELP1 PV was identified in all patients with available constitutional DNA ( n = 26); moreover, all tested familial trio ( n = 11) revealed that the PVs were inherited. Two of the 26 index cases from the French series had a family history of MB; pedigrees from these patients and from 1 additional Dutch family suggested a weak penetrance. Apart from MB, no cancer was associated with ELP1 PVs; second tumors reported in 4 patients occurred within the irradiation fields, in the usual time-lapse for expected radiotherapy-induced neoplasms.

          Conclusions

          The low penetrance, the “at risk’ age window limited to childhood and the narrow tumor spectrum, question the actual benefit of genetic screening in these patients and their family. Our results suggest restricting ELP1 germline sequencing to patients with SHH-MB, depending on the parents” request.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

          The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants. 1 In the past decade, sequencing technology has evolved rapidly with the advent of high-throughput next generation sequencing. By adopting and leveraging next generation sequencing, clinical laboratories are now performing an ever increasing catalogue of genetic testing spanning genotyping, single genes, gene panels, exomes, genomes, transcriptomes and epigenetic assays for genetic disorders. By virtue of increased complexity, this paradigm shift in genetic testing has been accompanied by new challenges in sequence interpretation. In this context, the ACMG convened a workgroup in 2013 comprised of representatives from the ACMG, the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP) to revisit and revise the standards and guidelines for the interpretation of sequence variants. The group consisted of clinical laboratory directors and clinicians. This report represents expert opinion of the workgroup with input from ACMG, AMP and CAP stakeholders. These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories including genotyping, single genes, panels, exomes and genomes. This report recommends the use of specific standard terminology: ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’ to describe variants identified in Mendelian disorders. Moreover, this recommendation describes a process for classification of variants into these five categories based on criteria using typical types of variant evidence (e.g. population data, computational data, functional data, segregation data, etc.). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a CLIA-approved laboratory with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or equivalent.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

            The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The landscape of genomic alterations across childhood cancers

              Pan-cancer analyses that examine commonalities and differences among various cancer types have emerged as a powerful way to obtain novel insights into cancer biology. Here we present a comprehensive analysis of genetic alterations in a pan-cancer cohort including 961 tumours from children, adolescents, and young adults, comprising 24 distinct molecular types of cancer. Using a standardized workflow, we identified marked differences in terms of mutation frequency and significantly mutated genes in comparison to previously analysed adult cancers. Genetic alterations in 149 putative cancer driver genes separate the tumours into two classes: small mutation and structural/copy-number variant (correlating with germline variants). Structural variants, hyperdiploidy, and chromothripsis are linked to TP53 mutation status and mutational signatures. Our data suggest that 7-8% of the children in this cohort carry an unambiguous predisposing germline variant and that nearly 50% of paediatric neoplasms harbour a potentially druggable event, which is highly relevant for the design of future clinical trials.
                Bookmark

                Author and article information

                Contributors
                Journal
                Neurooncol Adv
                Neurooncol Adv
                noa
                Neuro-Oncology Advances
                Oxford University Press (US )
                2632-2498
                Jan-Dec 2024
                15 May 2024
                15 May 2024
                : 6
                : 1
                : vdae075
                Affiliations
                Molecular Predictors and New Targets in Oncology, Inserm U981 Team “Genomics and Oncogenesis of Pediatric Brain Tumors,” Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Department of Pathology and Diagnostic, Prognostic and Theranostic Medicine, Somatic Genetic Unit, Institut Curie, Paris Sciences Lettres Research University , Paris, France
                Department of Pathology and Diagnostic, Prognostic and Theranostic Medicine, Somatic Genetic Unit, Institut Curie, Paris Sciences Lettres Research University , Paris, France
                Department of Neuropathology, Sainte Anne Hospital , Paris, France
                Pediatric Hematology and Oncology Department, Strasbourg University Hospital, University of Strasbourg , Strasbourg, France
                Department of Clinical Genetics, Strasbourg University Hospital , Strasbourg, France
                Department of Genetics, University Medical Center Utrecht , Utrecht, the Netherlands
                Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021 , Orsay, France
                Institut Curie, Paris Sciences Lettres Research University, CNRS UMR, INSERM , Orsay, France
                Department of Genetics, Institut Curie, Paris Sciences Lettres Research University , Paris, France
                Department of Genetics, Institut Curie, Paris Sciences Lettres Research University , Paris, France
                Necker-Enfants Malades University Hospital, Department of Pediatric Neurosurgery, Paris-Cité University , Paris, France
                Necker-Enfants Malades University Hospital, Department of Pediatric Neurosurgery, Paris-Cité University , Paris, France
                Cancer Genetics Unit, Department of Biology and Pathology, Institut Gustave Roussy , Villejuif, France
                Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Molecular Predictors and New Targets in Oncology, Inserm U981 Team “Genomics and Oncogenesis of Pediatric Brain Tumors,” Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay , Villejuif, France
                National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy , Villejuif, France
                Psycho-Oncology Unit, Interdisciplinary Department of Supportive Care, Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Université Paris Cité , SIREDO Pediatric Cancer Center, Institut Curie, Paris, France
                SIREDO Center (Care, Innovation Research in Pediatric, Adolescent and Young Adult Oncology), Institut Curie , Paris, France
                SIREDO Center (Care, Innovation Research in Pediatric, Adolescent and Young Adult Oncology), Institut Curie , Paris, France
                Pediatric Hematology and Oncology Institut, Centre Léon Berard , Lyon, France
                Clinical Oncogenetics Unit, Department of Prevention and Public Health, Centre Léon Bérard , Lyon, France
                Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Nancy , Vandœuvre-lès-Nancy, France
                Pediatric Hematology and Oncology Department, Angers University Hospital , Nancy, France
                Department of Genetics, Angers University Hospital , Angers, France
                Department of Genetics, Grenoble University Hospital , Grenoble, France
                Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Grenoble , Grenoble, France
                Department of Genetics, Centre François Baclesse , Caen, France
                Pediatric Hematology and Oncology Department, Caen University Hospital , Caen, France
                Department of Genetics, Toulouse University Hospital , Toulouse, France
                Pediatric Hematology and Oncology Department, Toulouse University Hospital , Toulouse, France
                Department of Medical Genetics, Montpellier University Hospital, Institute for Neurosciences of Montpellier, Univ Montpellier, INSERM , Montpellier, France
                Laboratory of Neuropathology, Centre Oscar Lambret , Lille, France
                INSERM U830, Cancer, Heterogeneity, Instability and Plasticity Laboratory Institut Curie , Paris, France
                Université Paris Sud, Université Paris-Saclay, CNRS UMR 3347, INSERM U1021 , Orsay, France
                Institut Curie, Paris Sciences Lettres Research University, CNRS UMR, INSERM , Orsay, France
                Molecular Predictors and New Targets in Oncology, Inserm U981 Team “Genomics and Oncogenesis of Pediatric Brain Tumors,” Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay , Villejuif, France
                Université Paris Cité , SIREDO Pediatric Cancer Center, Institut Curie, Paris, France
                SIREDO Center (Care, Innovation Research in Pediatric, Adolescent and Young Adult Oncology), Institut Curie , Paris, France
                INSERM U830, Cancer, Heterogeneity, Instability and Plasticity Laboratory Institut Curie , Paris, France
                Author notes
                Corresponding Author: Léa Guerrini-Rousseau, MD, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France ( lea.guerrini-rousseau@ 123456gustaveroussy.fr )
                Corresponding Author: Franck Bourdeaut, MD, PhD, SIREDO –Institut Curie, 26 rue d’Ulm, 75005 Paris, France ( franck.bourdeaut@ 123456curie.fr ).
                Author information
                https://orcid.org/0000-0003-0050-5407
                https://orcid.org/0000-0003-4076-9642
                https://orcid.org/0000-0002-3405-1944
                https://orcid.org/0000-0002-9046-257X
                https://orcid.org/0000-0003-4773-3001
                https://orcid.org/0000-0001-9286-4831
                https://orcid.org/0000-0001-5993-8077
                https://orcid.org/0000-0001-9489-6781
                Article
                vdae075
                10.1093/noajnl/vdae075
                11221071
                38962751
                c172c773-bdb3-4ee2-886c-e300936f9ae6
                © The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 03 July 2024
                Page count
                Pages: 12
                Funding
                Funded by: Foundation Gustave Roussy;
                Funded by: INCa PRTK-19-027;
                Funded by: St Baldrick’s Foundation;
                Funded by: INCa PRTK-19-027;
                Funded by: ADAM and Gustave Roussy;
                Categories
                Clinical Investigations
                AcademicSubjects/MED00300
                AcademicSubjects/MED00310

                cancer predisposition syndrome,elp1,medulloblastoma,pathogenic variant

                Comments

                Comment on this article